HIGHLIGHTS
- who: January and colleagues from the Beijing University of Chinese Medicine, China have published the Article: Salvianolate injection for hypertensive nephropathy patients who were using valsartan: A systematic review and meta-analysis, in the Journal: (JOURNAL) of 22/Oct/2022
- what: Current studies suggest that active control of BP and reduction of urinary protein (UP) are the main goals of the treatment of HN (Wiederkehr et_al, 2005). The analysis showed that salvianolate combined with the valsartan group had a better effect on reducing Cys-C (MD=-1.04, 95%CI: -1.63 to -0.45 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.